Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Inflexal V 2009/2010 Influenza Vaccine
NCT01306253Phase 4Completed
- Sponsor
- Crucell
- Start
- Jun 2009
- Primary completion
- Jun 2009
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Inflexal V in influenza (2 arms), sponsored by Crucell. Primary endpoints: Seroconversion at Day 22, Seroprotection at Day 22 and 1 more. Started Jun 2009; status: completed.
02
Drugs
Inflexal V
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01306253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01306253.